794 related articles for article (PubMed ID: 24259602)
1. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
2. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
3. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Ufer M
Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
8. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
9. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Gong IY; Kim RB
Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
[TBL] [Abstract][Full Text] [Related]
10. Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Giorgi MA; Cohen Arazi H; Gonzalez CD; Di Girolamo G
Expert Opin Pharmacother; 2011 Mar; 12(4):567-77. PubMed ID: 21254865
[TBL] [Abstract][Full Text] [Related]
11. Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
Klauser W; Dütsch M
Musculoskelet Surg; 2013 Dec; 97(3):189-97. PubMed ID: 24249360
[TBL] [Abstract][Full Text] [Related]
12. Drug and dietary interactions of the new and emerging oral anticoagulants.
Walenga JM; Adiguzel C
Int J Clin Pract; 2010 Jun; 64(7):956-67. PubMed ID: 20584229
[TBL] [Abstract][Full Text] [Related]
13. The new oral anticoagulants: a challenge for hospital formularies.
Merli GJ
Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101
[TBL] [Abstract][Full Text] [Related]
14. Perioperative management of patients on new oral anticoagulants.
Lai A; Davidson N; Galloway SW; Thachil J
Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
[TBL] [Abstract][Full Text] [Related]
15. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
17. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
18. New oral anticoagulants--a review.
Ghanima W; Atar D; Sandset PM
Tidsskr Nor Laegeforen; 2013 Oct; 133(18):1940-5. PubMed ID: 24084970
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation - new frontiers in anticoagulation.
Thomas R; Page PL; Mitchell AR
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):45-9. PubMed ID: 25088125
[TBL] [Abstract][Full Text] [Related]
20. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
